share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K:外国发行人报告(业绩相关)
美股SEC公告 ·  09/27 04:38

Moomoo AI 已提取核心信息

Alterity Therapeutics Limited, a development stage enterprise, has filed its corporate governance statement for the financial year ended June 30, 2024, with the Securities and Exchange Commission (SEC) as part of its Form 6-K filing for September 2024. The statement, which is current as of September 26, 2024, details the company's compliance with the ASX Corporate Governance Council's recommendations. It includes disclosures on board composition, diversity policy, risk management, and other key governance aspects. The company has chosen to provide this information on its website, with specific URLs given for each section of the corporate governance statement. Alterity Therapeutics has also confirmed that it does not have a nomination committee, instead disclosing the processes it employs to address board succession issues and ensure an appropriate balance of skills and diversity. The company has followed the majority of the recommendations, with detailed disclosures provided for each. The full corporate governance statement is available on Alterity Therapeutics' website, offering transparency to investors and stakeholders regarding the company's governance practices and policies.
Alterity Therapeutics Limited, a development stage enterprise, has filed its corporate governance statement for the financial year ended June 30, 2024, with the Securities and Exchange Commission (SEC) as part of its Form 6-K filing for September 2024. The statement, which is current as of September 26, 2024, details the company's compliance with the ASX Corporate Governance Council's recommendations. It includes disclosures on board composition, diversity policy, risk management, and other key governance aspects. The company has chosen to provide this information on its website, with specific URLs given for each section of the corporate governance statement. Alterity Therapeutics has also confirmed that it does not have a nomination committee, instead disclosing the processes it employs to address board succession issues and ensure an appropriate balance of skills and diversity. The company has followed the majority of the recommendations, with detailed disclosures provided for each. The full corporate governance statement is available on Alterity Therapeutics' website, offering transparency to investors and stakeholders regarding the company's governance practices and policies.
alterity therapeutics有限公司,作为一家发展阶段企业,已提交截至2024年6月30日财政年度的公司治理声明给证券交易委员会(SEC),作为其2024年9月提交的6-k表格的一部分。该声明截至2024年9月26日仍然有效,详细说明了公司遵守澳交所公司治理委员会的建议。其中包括有关董事会组成、多样性政策、风险管理和其他关键治理方面的披露。公司选择在其网站上提供这些信息,为公司治理声明的每个部分提供了特定的URL。alterity therapeutics还确认公司没有提名委员会,而是披露了其处理董事会继任问题并确保技能和多样性适当平衡的流程。公司已遵循大多数建议,并为每项建议提供了详细的披露。整份公司治理声明可在alterity therapeutics的网站上获得,为投资者和利益相关者提供了关于公司治理实践和政策的透明度。
alterity therapeutics有限公司,作为一家发展阶段企业,已提交截至2024年6月30日财政年度的公司治理声明给证券交易委员会(SEC),作为其2024年9月提交的6-k表格的一部分。该声明截至2024年9月26日仍然有效,详细说明了公司遵守澳交所公司治理委员会的建议。其中包括有关董事会组成、多样性政策、风险管理和其他关键治理方面的披露。公司选择在其网站上提供这些信息,为公司治理声明的每个部分提供了特定的URL。alterity therapeutics还确认公司没有提名委员会,而是披露了其处理董事会继任问题并确保技能和多样性适当平衡的流程。公司已遵循大多数建议,并为每项建议提供了详细的披露。整份公司治理声明可在alterity therapeutics的网站上获得,为投资者和利益相关者提供了关于公司治理实践和政策的透明度。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息